Key facts
- This page summarizes Steven H. Stein's Form 4/A - Amendment filing for INCYTE CORP (INCY).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 May 2026, 16:02.
Steven H. Stein - 06 May 2026 Form 4/A - Amendment Insider Report for INCYTE CORP (INCY)
- Reporting relationship
- CMO & Head of Late-Stage Dev.
- Issuer ticker
- INCY
- Reported as of
- 06 May 2026
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 20 May 2026, 16:02:11 UTC
- Original report date
- 17 Apr 2026
- Prior SEC filing
- 17 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Feeney, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven H. Stein filed Form 4/A - Amendment for INCYTE CORP (INCY) on 20 May 2026.
Change
- Previous filing in this sequence was filed on 17 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reporting Owners (1)
CIK 0001673776
Primary reporting owner
Stein Steven H
- Relationship
- CMO & Head of Late-Stage Dev.
- Address
- 1801 AUGUSTINE CUT-OFF, WILMINGTON
- Signature
- /s/ Elizabeth Feeney, Attorney-In-Fact
- Signature date
- 20 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INCY
transaction
Common Stock
Award
- Transaction value
- Shares
- +44,124
- Change %
- +129%
- Price
- $0.000000*
- Shares after
- 78,327
- Date
- 06 May 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on May 6, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuer's Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded.
Footnote F2
This Form 4/A amends the original Form 4, filed on April 17, 2026, to reflect the Compensation Committee's determination on May 6, 2026 relating to the achievement of the performance criteria, which superseded the Compensation Committee's initial determination on April 15, 2026.
Footnote F3
Including this certification of performance shares, this includes an aggregate of 78,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.